Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic differences in murine AML bone marrow samples with different Gab2 genotypes

ABSTRACT: Transcriptomic differences in murine AML bone marrow samples with different Gab2 genotypes

PROVIDER: PRJNA757092 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15569681_1.fastq.gz	Fastqsanger.gz
	SRR15569681_2.fastq.gz	Fastqsanger.gz
	SRR15569682_1.fastq.gz	Fastqsanger.gz
	SRR15569682_2.fastq.gz	Fastqsanger.gz
	SRR15569683_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Transcriptomic differences in murine AML bone marrow samples with different Gab2 genotypes

Project description:Internal tandem duplications (ITD) of FLT3 predict poor prognosis in acute myeloid leukemia (AML) and often co-exist with inactivating DNMT3A mutations. In a genetically modified mouse model harboring these genetic aberrations, we analyzed the role of the adaptor protein Gab2 in this disease. We observed Gab2 to be essential for the development of Flt3-ITD driven AML in vivo, which was corroborated by RNA sequencing data of whole murine bone marrow with different Gab2 genotypes

2022-04-27 | GSE182624 | GEO

Effect on bone marrow mesenchymal stromal cells of mouse models of acute myeloid leukemia of different genotypes

Project description:We found that cells of acute myeloid leukemia (AML) affect the transcriptome of mesenchymal stromal cells (MSC) in bone marrow (BM) involved by AML. Gene expression in BM-MSC of AML-bearing mice differed from that in BM-MSC of control mice; some gene changes were the same across different types of AML produced by well-known fusion oncogenes, while others were specific to certain genotypes. There were notable differences between the effects of tp53 WT and tp53-/- AML with the same oncogene (MLL&FLT3-ITD); these were supported by in vitro experiments in which normal BM-derived MSC were cultured with the same tp53 WT and tp53-/- pair of AML cells.

2017-06-14 | GSE97194 | GEO

pediatric AML and normal bone marrow

Project description:This series represents leukemic samples obtained from pediatric AML patients at diagnosis and control normal bone marrow samples. Keywords: other

2005-01-28 | GSE2191 | GEO

evolution of genotypes and differences - affy_gnp07_regeneome_cotton

Project description:affy_gnp07_regeneome_cotton - evolution of genotypes and differences - Genes involved in somatic embryogenesis

2012-06-01 | GSE31005 | GEO

miRNA expression in bone marrow of an AML patient and CD34 cells of healthy individuals

Project description:miRNA expression in a patient with AML comparing with pooled CD34 hematopoietic progenitor cells from 5 healthy volunteers RNA from bone marrow of a patient with AML with more than 90% blast and RNA pooled from 5 volunteers with CD34+ cells selected by automacs from bone marrow

2010-09-21 | E-GEOD-24222 | biostudies-arrayexpress

Genome-wide effect of AML engraftment on bone marrow endothelial cells

Project description:We analysed the transcriptional signature in endothelial cells extracted from the bone marrow of mice engrafted with human AML and compared it to the one of mice engrafted with human normal hematopoietic cells

2017-09-11 | GSE88905 | GEO

Differences in bone marrow serum proteins in acute myeloid leukemia patients and normal controls

Project description:we evaluated cytokine profiling of bone marrow serum samples in AML patients and healthy controls. Protein expression profiling of serum from 9 AML patients and 5 healthy controls was obtained using biotinylated antibody chip. Total 507 cytokines and growth factors were analyzed. Compared with healthy people, AML patients expressed 31 signature proteins, among which, 27 were found significantly higher expressed and 4 proteins were lower.

2019-12-17 | GSE141930 | GEO

Transcriptional Alterations in Bone Marrow Mesenchymal Stromal Cells derived from Acute Myeloid Leukemia patients (AML BM-MSC)

Project description:The aim of the study was to get insights into transcriptional alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients We compared the global gene expression profile from AML BM-MSC (n=19) to healthy donor (HD) controls (HD BM-MSC n=4) AML BM-MSC and HD BM-MSC were isolated from bone marrow aspirates (see below) and hybridized on an Affymetrix HG-U133 Plus 2.0 GeneChip

2016-07-27 | E-GEOD-84881 | biostudies-arrayexpress

Expression data from human AML blasts and healthy CD34+ bone marrow cells

Project description:Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and the bone marrow (BM) stroma is a major mechanism underlying therapy resistance in AML. Lenalidomide and pomalidomide, a new generation immunomodulatory drugs (IMiDs), possess pleiotropic anti-leukemic properties including potent immune-modulating effects and are commonly used in hematological malignances associated with intrinsic dysfunctional BM such as myelodysplastic syndromes and multiple myeloma. Whether IMiDs may improve the efficacy of current standard treatment in AML remains understudied. Here, we have exploited in vitro and in vivo preclinical AML models to analyze whether IMiDs potentiate the efficacy of AraC/Iradubicin (standard AML chemotherapy) by interfering with the BM stroma-mediated chemoresistance. We report that lenalidomide and pomalidomide have cytotoxic effects on neither AML cells nor BM-MSCs, but they increase the immunosuppressive/immunomodulatory properties of BM-MSCs. When combined with AraC and Idarubicin, IMiDs fail to circumvent BM stroma-mediated resistance of AML cells in vitro and in vivo but induce robust extramedullary mobilization of AML cells. When administered as a single agent, lenalidomide highly mobilizes AML cells, but not healthy CD34+ cells, to peripheral blood (PB) likely through specific downregulation of CXCR4 in AML blasts. Global gene expression profiling supports a migratory/mobilization gene signature in lenalidomide-treated AML blasts but not in CD34+ cells. Collectively, IMiDs mobilize AML blasts to PB through downregulation of CXCR4 but do not improve AraC/Idarubicin activity in a preclinical model of AML.

2019-05-17 | GSE106748 | GEO

A comparative study of bone marrow and peripheral blood CD34+ myeloblasts in acute myeloid leukaemia

Project description:To examine the differences between bone marrow (BM) and peripheral blood (PB) myeloblasts in acute myeloid leukaemia (AML), we compared CD34+ myeloblasts of paired BM and peripheral blood (PB) samples from AML patients using microarray.

2008-09-30 | GSE12326 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data